Extra Payments Motivate Sobriety and Employment among People Recovering from Addiction
After a yearlong study of people with opioid dependence, Johns Hopkins Medicine researchers report evidence that adding $8 an hour to their paychecks may help those in recovery stay drug free longer, as well as encourage them to get and hold regular jobs.
The researchers say poverty is an independent risk factor for drug abuse that treatment plans largely ignore.
In a report on the study, described in the Journal of Epidemiology & Community Health online Feb. 21, the investigators say their intervention could be used widely in low-income neighborhoods as a way to promote employment, reduce drug use and help those ravaged by the opioid crisis better integrate back into their communities.
“We were hoping to have a positive result from our study, but I don’t think we expected it to work quite so well,” says August Holtyn, Ph.D., assistant professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine.
Holtyn says this financial stimulus was the brainchild of Kenneth Silverman, Ph.D., professor of psychiatry and behavioral sciences at the Johns Hopkins University School of Medicine. For more than two decades, he has been developing therapeutic workplace strategies to help promote employment while reducing drug use.
For this study, the research team recruited 91 participants from the Center for Learning and Health on the Johns Hopkins Bayview Medical Center campus in Baltimore, Maryland. The participants were ages 21 to 74 and were paid $8 an hour with an optional $2 bonus as they went through three months of job training and drug testing. All participants were then invited to work with an employment specialist to help them get a job in the community.
About 56% of the participants were African American, about 40% were white and 55% were men. All participants were being treated with methadone or buprenorphine for opioid dependence.
Of the participants, 98% lived in poverty according to the 2018 poverty thresholds set by the U.S. Census Bureau, and almost 75% were unemployed for at least three years before the study.
Forty-four participants were randomly chosen to receive a wage supplement of $8 per hour after the first three months, and the 47 people in the other group received no extra financial incentives beyond the first three months of training and drug testing.
All participants underwent regular urine screens three times each week that became more intermittent if the person remained drug-free. If a participant receiving the wage supplement tested positive for cocaine or opioids, the wage supplement was reduced to $1 and more frequent testing resumed. For each day participants were drug free, the wage supplement rose $1 per hour until reaching the maximum of $8 per hour.
During the yearlong intervention, 65% of people with wage supplements provided urine samples free of opioids and cocaine, compared to 45% of those without wage supplements.
People with wage supplements were also 2.9 times more likely to get a job and 2.7 times more likely to rise out of poverty by the end of the year than those without wage supplements.
“Following this study, the vast majority of unemployed people that participated entered into the workforce with minimum wage positions, so we think the wage supplement is helpful in providing motivation to keep jobs that at times can be stressful and difficult,” says Holtyn. She says participants worked in construction, grocery stores, the food service industry, house cleaning and delivery.
The researchers caution that because the wage supplements and drug testing stopped after the study period, they will continue to follow participants for another year to see if the reduced drug use and consistent employment effects persist. They are also testing their wage supplement intervention with homeless adults who have alcohol use disorder.
Additional authors include Forrest Toegel, Shrinidhi Subramaniam, Brantley Jarvis, Jeannie-Marie Leoutsakos and Michael Fingerhood.
Funding for the study was provided by the National Institute on Drug Abuse (R01DA037314 and T32DA07209).
The researchers have no conflicts of interest to report.